Larimar Therapeutics, Inc. (LRMR)
| Market Cap | 207.72M -42.9% |
| Revenue (ttm) | n/a |
| Net Income | -172.61M |
| EPS | -1.93 |
| Shares Out | 104.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,179,736 |
| Open | 2.090 |
| Previous Close | 2.090 |
| Day's Range | 1.950 - 2.115 |
| 52-Week Range | 1.950 - 6.420 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 14.40 (+623.62%) |
| Est. Earnings | Nov 4, 2026 |
About LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for LRMR stock is "Strong Buy." The 12-month stock price target is $14.4, which is an increase of 623.62% from the latest price.
News
Larimar Therapeutics appoints John Harlow as COO
Larimar Therapeutics (LRMR) announced the appointment of John Harlow as President and COO, effective September 29, reporting to Carole Ben-Maimon, M.D., Larimar’s CEO. Harlow joins Larimar with more t...
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea...
Larimar Therapeutics assumed with an Outperform at Leerink
Leerink analyst Basma Radwan assumed coverage of Larimar Therapeutics (LRMR) with an Outperform rating and a price target of $13, up from $12. The company’s only product, nomlabofusp, is differentiate...
Larimar Therapeutics price target lowered to $11 from $12 at Wedbush
Wedbush lowered the firm’s price target on Larimar Therapeutics (LRMR) to $11 from $12 and keeps an Outperform rating on the shares. The firm says that the most important in…
Larimar Therapeutics reports Q2 EPS (30c), consensus (38c)
“This is a defining period for Larimar as we advance nomlabofusp toward potential approval, supported by a clear path to submission, a robust data package, and continued clinical momentum,” said…
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
BALA CYNWYD, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas...
Larimar Therapeutics Earnings release: Q2 2026
Larimar Therapeutics released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Larimar Therapeutics Quarterly report: Q2 2026
Larimar Therapeutics has published its Q2 2026 quarterly earnings report on August 4, 2026.
Larimar Therapeutics Slides: Corporate presentation
Larimar Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 3, 2026.
Larimar Therapeutics director buys $167K in common stock
In a regulatory filing, Larimar Therapeutics (LRMR) disclosed that its director, Thomas Hamilton, bought 50,000 shares of common stock on July 6th in a total transaction size of $167K. Shares…
Larimar Therapeutics assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of Larimar Therapeutics (LRMR) with a Buy rating and $10 price target The company’s biologics license application for nomlabofusp later this year is likely to receive…
Larimar Therapeutics price target lowered to $5 from $7 at Baird
Baird analyst Christopher Chen lowered the firm’s price target on Larimar Therapeutics (LRMR) to $5 from $7 and keeps an Outperform rating on the shares. The firm updated its model…
Larimar Therapeutics selloff a buying opportunity, says Citi
Citi recommends buying Larimar Therapeutics (LRMR) shares on yesterday’s weakness. FDA feedback indicates the company’s current data package is sufficient to support an application submission under ac...
Larimar stumbles on safety news even as BLA submission kicks off
Larimar Therapeutics (LRMR) shares slid on Monday after the company reported new safety findings from its open label study of nomlabofusp for Friedreich’s Ataxia. The update showed 21 discontinuations...
Larimar Therapeutics Transcript: Study update
Nomlabofusp demonstrated sustained increases in frataxin and improvements in key clinical outcomes for Friedreich's ataxia, with a favorable safety profile and strong patient interest. Rolling BLA submission is underway, and a global phase III trial will begin soon, targeting a broad patient population.
Larimar Therapeutics Press release: Study update
Larimar Therapeutics issued a press release on June 29, 2026, disclosing material business information to investors.
Larimar Therapeutics Slides: Study update
Larimar Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
Larimar Therapeutics submits first module of rolling BLA for nomlabofusp
Larimar Therapeutics (LRMR) announced it has submitted the first module of its rolling Biologics License Application submission to the FDA for accelerated approval of nomlabofusp; the remaining module...
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich's Ataxia
BALA CYNWYD, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas...
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich's Ataxia
BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas...
Larimar Therapeutics initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Larimar Therapeutics (LRMR) with an Overweight rating and $9 price target The company’s lead asset is nomlabofusp is a subcutaneously administered, recombinant fusion pr...
Larimar Therapeutics price target lowered to $12 from $13 at Wedbush
Wedbush lowered the firm’s price target on Larimar Therapeutics (LRMR) to $12 from $13 and keeps an Outperform rating on the shares. Most notable in the update, Larimar remains on…
Larimar Therapeutics price target lowered to $12 from $13 at Wedbush
Wedbush lowered the firm’s price target on Larimar Therapeutics (LRMR) to $12 from $13 and keeps an Outperform rating on the shares. Larimar remains on track to start its rolling…
Larimar Therapeutics reports Q1 EPS (31c), consensus (57c)
“We have strong momentum as we advance nomlabofusp towards potential approval for the treatment of adults and children with Friedreich’s ataxia. Our ongoing engagement with the U.S. Food and Drug…
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in se...